UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 69

Sortiert nach

A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma

The New England journal of medicine, 2003-06, Vol.348 (26), p.2609-2617

2003

Link zum Volltext

Verfügbarkeit prüfen

Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease

Cancer, 2004-08, Vol.101 (3), p.558-566

2004

Link zum Volltext

Verfügbarkeit prüfen

Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy

Annals of oncology, 2006-12, Vol.17 (12), p.1766-1771

2006

Link zum Volltext

Verfügbarkeit prüfen

Bevacizumab Use in Patients With Subtotal Resection of Newly Diagnosed Glioblastoma (GBM): A Secondary Analysis of NRG Oncology/RTOG 0825

International journal of radiation oncology, biology, physics, 2015-11, Vol.93 (3), p.S110-S110

2015

Link zum Volltext

Verfügbarkeit prüfen

Cyclin D1 positive follicular lymphoma

Journal of clinical pathology, 2009-09, Vol.62 (9), p.855-857

2009

Link zum Volltext

Verfügbarkeit prüfen

Frequency, Characteristics, and Reversibility of Peripheral Neuropathy During Treatment of Advanced Multiple Myeloma With Bortezomib

Journal of clinical oncology, 2006-07, Vol.24 (19), p.3113-3120

2006

Link zum Volltext

Verfügbarkeit prüfen

Motesanib Diphosphate in Progressive Differentiated Thyroid Cancer

The New England journal of medicine, 2008-07, Vol.359 (1), p.31-42

2008

Link zum Volltext

Verfügbarkeit prüfen

Pan-cancer analysis of clinical acquired resistance (AR) in BRAF-driven real-world cases

Annals of oncology, 2019-10, Vol.30, p.v762-v763

2019

Link zum Volltext

Verfügbarkeit prüfen

1878PD - Pan-cancer analysis of clinical acquired resistance (AR) in BRAF-driven real-world cases

Annals of oncology, 2019-10, Vol.30, p.v762-v763

2019

Link zum Volltext

Verfügbarkeit prüfen

Acquired Activated Protein C Resistance in Myeloma Patients with Venous Thromboembolic Events

British journal of haematology, 2003-12, Vol.123 (5), p.959-959

2003

Link zum Volltext

Verfügbarkeit prüfen

Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma : Final time-to-event results from the SUMMIT trial

Cancer, 2006-03, Vol.106 (6), p.1316-1319

2006

Link zum Volltext

Verfügbarkeit prüfen

Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone

Haematologica (Roma), 2006-07, Vol.91 (7), p.929

2006

Link zum Volltext

Verfügbarkeit prüfen

Abstract P6-13-04: IMPACt trial: MammaPrint and BluePrint molecular subtyping guide treatment decisions in breast cancer

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.P6-P6-13-04

2018

Link zum Volltext

Verfügbarkeit prüfen

Abstract OT1-13-01: MammaPrint, BluePrint, and full-genome data linked with clinical data to evaluate new gene expression profiles (FLEX)

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.OT1-13-01-OT1-13-01

2019

Link zum Volltext

Verfügbarkeit prüfen

Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma

Cancer, 2005-11, Vol.104 (10), p.2141-2148

2005

Link zum Volltext

Verfügbarkeit prüfen

Analogues of Luteinizing Hormone-Releasing Hormone Containing Cytotoxic Groups

Proceedings of the National Academy of Sciences - PNAS, 1992-02, Vol.89 (3), p.972-976

1992

Link zum Volltext

Verfügbarkeit prüfen

Abstract S5-07: SWOG S0500 – A randomized phase III trial to test the strategy of changing therapy versus maintaining therapy for metastatic breast cancer patients who have elevated circulating tumor cell (CTC) levels at first follow-up assessment

Cancer research (Chicago, Ill.), 2013-12, Vol.73 (24_Supplement), p.S5-S5-07

2013

Link zum Volltext

Verfügbarkeit prüfen

A Phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced‐dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients

Cancer, 2002-11, Vol.95 (10), p.2160-2168

2002

Link zum Volltext

Verfügbarkeit prüfen

Tryptophan Loading Modulates Light-Induced Responses in the Mammalian Circadian System

Journal of biological rhythms, 1995-03, Vol.10 (1), p.80-90

1995

Link zum Volltext

Verfügbarkeit prüfen

Receptors for Luteinizing hormone-releasing hormone (LHRH) in dunning R3327 prostate cancers and rat anterior pituitaries after treatment with a sustained delivery system of LHRH antagonist SB-75

Endocrinology (Philadelphia), 1990-12, Vol.127 (6), p.3052-3060

1990

Link zum Volltext

Verfügbarkeit prüfen

Prognostic factors of overall survival for patients with stage II colon cancer treated at Sparrow Hospital from 1996–2006

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.15089-15089

2008

Link zum Volltext

Verfügbarkeit prüfen

Highly Potent Metallopeptide Analogues of Luteinizing Hormone-Releasing Hormone

Proceedings of the National Academy of Sciences - PNAS, 1989-08, Vol.86 (16), p.6313-6317

1989

Link zum Volltext

Verfügbarkeit prüfen

First analysis of SWOG S0221: A phase III trial comparing chemotherapy schedules in high-risk early breast cancer

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.1004-1004

2011

Link zum Volltext

Verfügbarkeit prüfen

Acute hypersensitivity reaction to ferric gluconate in a premedicated patient

The Annals of pharmacotherapy, 2005-12, Vol.39 (12), p.2124

2005

Link zum Volltext

Verfügbarkeit prüfen

Highly Potent Analogues of Luteinizing Hormone-Releasing Hormone Containing D-phenylalanine Nitrogen Mustard in Position 6

Proceedings of the National Academy of Sciences - PNAS, 1989-08, Vol.86 (16), p.6318-6322

1989

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 69

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(64)
Mit Volltextzugriff
(63)

Publikationsform

Artikel
(69)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(39)
Female
(35)
Life Sciences & Biomedicine
(34)
Biological And Medical Sciences
(31)
Medical Sciences
(30)
Humans
(28)
Male
(26)
Animals
(22)
Oncology
(20)
Middle Aged
(17)
Aged
(16)
Adult
(15)
Gonadotropin-Releasing Hormone - Analogs & Derivatives
(15)
Tumors
(14)
Pharmacology. Drug Treatments
(13)
Antineoplastic Agents
(12)
Multiple Myeloma - Drug Therapy
(11)
Rats
(11)
Receptors, Lhrh - Metabolism
(11)
Aged, 80 And Over
(10)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma

Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease

Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy

Bevacizumab Use in Patients With Subtotal Resection of Newly Diagnosed Glioblastoma (GBM): A Secondary Analysis of NRG Oncology/RTOG 0825

Cyclin D1 positive follicular lymphoma

Frequency, Characteristics, and Reversibility of Peripheral Neuropathy During Treatment of Advanced Multiple Myeloma With Bortezomib

Motesanib Diphosphate in Progressive Differentiated Thyroid Cancer

Pan-cancer analysis of clinical acquired resistance (AR) in BRAF-driven real-world cases

1878PD - Pan-cancer analysis of clinical acquired resistance (AR) in BRAF-driven real-world cases

Acquired Activated Protein C Resistance in Myeloma Patients with Venous Thromboembolic Events

Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma : Final time-to-event results from the SUMMIT trial

Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone

Abstract P6-13-04: IMPACt trial: MammaPrint and BluePrint molecular subtyping guide treatment decisions in breast cancer

Abstract OT1-13-01: MammaPrint, BluePrint, and full-genome data linked with clinical data to evaluate new gene expression profiles (FLEX)

Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma

Analogues of Luteinizing Hormone-Releasing Hormone Containing Cytotoxic Groups

Abstract S5-07: SWOG S0500 – A randomized phase III trial to test the strategy of changing therapy versus maintaining therapy for metastatic breast cancer patients who have elevated circulating tumor cell (CTC) levels at first follow-up assessment

A Phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced‐dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients

Tryptophan Loading Modulates Light-Induced Responses in the Mammalian Circadian System

Receptors for Luteinizing hormone-releasing hormone (LHRH) in dunning R3327 prostate cancers and rat anterior pituitaries after treatment with a sustained delivery system of LHRH antagonist SB-75

Prognostic factors of overall survival for patients with stage II colon cancer treated at Sparrow Hospital from 1996–2006

Highly Potent Metallopeptide Analogues of Luteinizing Hormone-Releasing Hormone

First analysis of SWOG S0221: A phase III trial comparing chemotherapy schedules in high-risk early breast cancer

Acute hypersensitivity reaction to ferric gluconate in a premedicated patient

Highly Potent Analogues of Luteinizing Hormone-Releasing Hormone Containing D-phenylalanine Nitrogen Mustard in Position 6

Suchergebnisse filtern